Premium
Proteasome inhibitor‐associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature
Author(s) -
Nguyen Michelle Nadeau,
Nayernama Afrouz,
Jones S. Christopher,
Kanapuru Bindu,
Gormley Nicole,
Waldron Peter E.
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25832
Subject(s) - carfilzomib , medicine , thrombotic microangiopathy , bortezomib , adverse event reporting system , ixazomib , adverse effect , mantle cell lymphoma , adamts13 , lenalidomide , multiple myeloma , thalidomide , thrombotic thrombocytopenic purpura , proteasome inhibitor , population , oncology , pharmacology , gastroenterology , lymphoma , disease , platelet , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom